Litigation Details for Janssen Biotech, Inc. v. Amgen Inc. (D. Del. 2022)
✉ Email this page to a colleague
Janssen Biotech, Inc. v. Amgen Inc. (D. Del. 2022)
| Docket | ⤷ Try a Trial | Date Filed | 2022-11-29 |
| Court | District Court, D. Delaware | Date Terminated | 2023-05-23 |
| Cause | 35:271 Patent Infringement | Assigned To | Maryellen Noreika |
| Jury Demand | None | Referred To | |
| Parties | AMGEN INC. | ||
| Patents | 6,476,005; 7,700,739; 8,852,889; 9,217,168; 9,475,858; 9,663,810 | ||
| Attorneys | Scott P. Cooper | ||
| Link to Docket | External link to docket | ||
Biologic Drugs cited in Janssen Biotech, Inc. v. Amgen Inc.
The biologic drugs covered by the patents cited in this case are ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , ⤷ Try a Trial , and ⤷ Try a Trial .
Details for Janssen Biotech, Inc. v. Amgen Inc. (D. Del. 2022)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2022-11-29 | 1 | Exhibit H-N | $ 2,818 $ 2,176 $ 6,476 $ 5,860 Provided November 3, 2022, as part…obtain patents for our products and technology, the protection offered by our patents and patent applications…12) United States Patent (10) Patent No.: … Unitedet States Patent ( 10) Patent No .: … severely active UC in patents, published patent applications and publications cited | External link to document |
| 2023-03-07 | 46 | Redacted Document | Janssen owns U.S. Patent Nos. 9,475,858 (“the ’858 patent”), 8,852,889 (“the ’889 patent”), 9,217,168 (“…the STELARA® compound patent (the ’734 patent) and UC patent (the ’307 patent), Janssen filed its initial…awarded a patent directed to its novel anti-IL-12 antibody, U.S. Patent No. 6,902,734 (“the ’734 patent”), …the ’168 patent”), and 9,663,810 (“the ’810 patent”) (collectively, “the Manufacturing Patents”). Each…least five Janssen patents: the ’307 patent, and each of the four Manufacturing Patents (the ’858, ’889, | External link to document |
| 2023-03-13 | 48 | Redacted Document | modifications. The first—in U.S. Patent No. 9,217,168 (the “’168 patent”)—is a novel method of controlling… Amgen infringes two patents: a compound patent and a method of treatment patent. D.I. 1 (“Compl.”). …relief based only on two of those patents (the “Manufacturing Patents”).1 …developed and acquired various patents, including the two Manufacturing Patents—directed to using living cells… B. The Manufacturing Patents Janssen’s Manufacturing Patents resulted from substantial investment | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
